blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3380107

EP3380107 - COMPOSITIONS AND METHODS OF USE OF NANO ANTI-RADICAL THERAPEUTICS TO INHIBIT CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  19.01.2024
Database last updated on 19.10.2024
FormerThe patent has been granted
Status updated on  10.02.2023
FormerGrant of patent is intended
Status updated on  06.10.2022
FormerExamination is in progress
Status updated on  30.10.2020
FormerRequest for examination was made
Status updated on  31.08.2018
FormerThe international publication has been made
Status updated on  02.06.2017
Most recent event   Tooltip18.10.2024Lapse of the patent in a contracting state
New state(s): BE		published on 20.11.2024 [2024/47]
Applicant(s)For all designated states
Antiradical Therapeutics LLC
2329 N Career Avenue
Suite 114
Sioux Falls, SD 57107-1363 / US
[2018/40]
Inventor(s)01 / HSIA, Jen-Chang
2400 Via Mariposa West
Unite 3E
Laguna Woods, CA 92637 / US
 [2021/29]
Former [2018/40]01 / HSAI, Jen-Chang
2400 Via Mariposa West
Unite 3E
Laguna Woods, CA 92637 / US
Representative(s)Murgitroyd & Company
165-169 Scotland Street
Glasgow G5 8PL / GB
[N/P]
Former [2023/11]Murgitroyd & Company
Murgitroyd House
165-169 Scotland Street
Glasgow G5 8PL / GB
Former [2018/40]Hanna Moore + Curley
Garryard House
25/26 Earlsfort Terrace
Dublin 2, D02 PX51 / IE
Application number, filing date16869267.123.11.2016
[2018/40]
WO2016US63594
Priority number, dateUS201562259485P24.11.2015         Original published format: US 201562259485 P
[2018/40]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017091722
Date:01.06.2017
Language:EN
[2017/22]
Type: A1 Application with search report 
No.:EP3380107
Date:03.10.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 01.06.2017 takes the place of the publication of the European patent application.
[2018/40]
Type: B1 Patent specification 
No.:EP3380107
Date:15.03.2023
Language:EN
[2023/11]
Search report(s)International search report - published on:US01.06.2017
(Supplementary) European search report - dispatched on:EP18.07.2019
ClassificationIPC:A61K35/14, A61P35/00, A61K31/337, A61K31/445, A61K47/64
[2019/34]
CPC:
A61K31/445 (EP,US); A61K47/643 (EP,US); A61K31/337 (EP,US);
A61P35/00 (EP,US)
Former IPC [2018/40]A61K35/14
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/40]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG VON NANO-ANTIRADIKALEN THERAPEUTIKA ZUR HEMMUNG VON KREBS[2018/40]
English:COMPOSITIONS AND METHODS OF USE OF NANO ANTI-RADICAL THERAPEUTICS TO INHIBIT CANCER[2018/40]
French:COMPOSITIONS ET PROCÉDÉS D'UTILISATION D'AGENTS THÉRAPEUTIQUES DE TYPE NANOPARTICULES ANTIRADICALAIRES POUR INHIBER LE CANCER[2018/40]
Entry into regional phase20.06.2018National basic fee paid 
20.06.2018Search fee paid 
20.06.2018Designation fee(s) paid 
20.06.2018Examination fee paid 
Examination procedure20.06.2018Examination requested  [2018/40]
20.06.2018Date on which the examining division has become responsible
14.02.2020Amendment by applicant (claims and/or description)
30.10.2020Despatch of a communication from the examining division (Time limit: M04)
01.04.2021Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
10.06.2021Reply to a communication from the examining division
31.01.2022Despatch of a communication from the examining division (Time limit: M04)
24.02.2022Reply to a communication from the examining division
20.04.2022Despatch of a communication from the examining division (Time limit: M04)
15.08.2022Reply to a communication from the examining division
07.10.2022Communication of intention to grant the patent
30.01.2023Fee for grant paid
30.01.2023Fee for publishing/printing paid
30.01.2023Receipt of the translation of the claim(s)
Opposition(s)18.12.2023No opposition filed within time limit [2024/08]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
10.06.2021Request for further processing filed
10.06.2021Full payment received (date of receipt of payment)
Request granted
21.06.2021Decision despatched
Fees paidRenewal fee
20.06.2018Renewal fee patent year 03
15.11.2019Renewal fee patent year 04
10.05.2021Renewal fee patent year 05
30.11.2021Renewal fee patent year 06
30.11.2022Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
30.11.202005   M06   Fee paid on   10.05.2021
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT15.03.2023
CZ15.03.2023
DK15.03.2023
EE15.03.2023
ES15.03.2023
FI15.03.2023
HR15.03.2023
IT15.03.2023
LT15.03.2023
LV15.03.2023
MC15.03.2023
NL15.03.2023
PL15.03.2023
RO15.03.2023
RS15.03.2023
SE15.03.2023
SI15.03.2023
SK15.03.2023
SM15.03.2023
NO15.06.2023
GR16.06.2023
IS15.07.2023
PT17.07.2023
IE23.11.2023
LU23.11.2023
BE30.11.2023
CH30.11.2023
[2024/47]
Former [2024/46]AT15.03.2023
CZ15.03.2023
DK15.03.2023
EE15.03.2023
ES15.03.2023
FI15.03.2023
HR15.03.2023
IT15.03.2023
LT15.03.2023
LV15.03.2023
MC15.03.2023
NL15.03.2023
PL15.03.2023
RO15.03.2023
RS15.03.2023
SE15.03.2023
SI15.03.2023
SK15.03.2023
SM15.03.2023
NO15.06.2023
GR16.06.2023
IS15.07.2023
PT17.07.2023
IE23.11.2023
LU23.11.2023
CH30.11.2023
Former [2024/34]AT15.03.2023
CZ15.03.2023
DK15.03.2023
EE15.03.2023
ES15.03.2023
FI15.03.2023
HR15.03.2023
IT15.03.2023
LT15.03.2023
LV15.03.2023
MC15.03.2023
NL15.03.2023
PL15.03.2023
RO15.03.2023
RS15.03.2023
SE15.03.2023
SI15.03.2023
SK15.03.2023
SM15.03.2023
NO15.06.2023
GR16.06.2023
IS15.07.2023
PT17.07.2023
LU23.11.2023
CH30.11.2023
Former [2024/32]AT15.03.2023
CZ15.03.2023
DK15.03.2023
EE15.03.2023
ES15.03.2023
FI15.03.2023
HR15.03.2023
IT15.03.2023
LT15.03.2023
LV15.03.2023
MC15.03.2023
NL15.03.2023
PL15.03.2023
RO15.03.2023
RS15.03.2023
SE15.03.2023
SI15.03.2023
SK15.03.2023
SM15.03.2023
NO15.06.2023
GR16.06.2023
IS15.07.2023
PT17.07.2023
Former [2024/26]AT15.03.2023
CZ15.03.2023
DK15.03.2023
EE15.03.2023
ES15.03.2023
FI15.03.2023
HR15.03.2023
IT15.03.2023
LT15.03.2023
LV15.03.2023
NL15.03.2023
PL15.03.2023
RO15.03.2023
RS15.03.2023
SE15.03.2023
SI15.03.2023
SK15.03.2023
SM15.03.2023
NO15.06.2023
GR16.06.2023
IS15.07.2023
PT17.07.2023
Former [2024/10]AT15.03.2023
CZ15.03.2023
DK15.03.2023
EE15.03.2023
ES15.03.2023
FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
NL15.03.2023
PL15.03.2023
RO15.03.2023
RS15.03.2023
SE15.03.2023
SI15.03.2023
SK15.03.2023
SM15.03.2023
NO15.06.2023
GR16.06.2023
IS15.07.2023
PT17.07.2023
Former [2023/50]AT15.03.2023
CZ15.03.2023
EE15.03.2023
ES15.03.2023
FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
NL15.03.2023
PL15.03.2023
RO15.03.2023
RS15.03.2023
SE15.03.2023
SK15.03.2023
SM15.03.2023
NO15.06.2023
GR16.06.2023
IS15.07.2023
PT17.07.2023
Former [2023/49]AT15.03.2023
CZ15.03.2023
EE15.03.2023
ES15.03.2023
FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
NL15.03.2023
RO15.03.2023
RS15.03.2023
SE15.03.2023
SM15.03.2023
NO15.06.2023
GR16.06.2023
PT17.07.2023
Former [2023/48]AT15.03.2023
EE15.03.2023
ES15.03.2023
FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
NL15.03.2023
RS15.03.2023
SE15.03.2023
SM15.03.2023
NO15.06.2023
GR16.06.2023
PT17.07.2023
Former [2023/46]ES15.03.2023
FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
NL15.03.2023
RS15.03.2023
SE15.03.2023
SM15.03.2023
NO15.06.2023
GR16.06.2023
PT17.07.2023
Former [2023/38]FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
NL15.03.2023
RS15.03.2023
SE15.03.2023
NO15.06.2023
GR16.06.2023
Former [2023/37]FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
RS15.03.2023
SE15.03.2023
NO15.06.2023
GR16.06.2023
Former [2023/36]FI15.03.2023
HR15.03.2023
LT15.03.2023
LV15.03.2023
RS15.03.2023
SE15.03.2023
NO15.06.2023
Former [2023/35]HR15.03.2023
LT15.03.2023
RS15.03.2023
NO15.06.2023
Former [2023/34]LT15.03.2023
RS15.03.2023
Former [2023/33]LT15.03.2023
Documents cited:Search[A]US5840701  (HSIA JEN-CHANG [US]) [A] 1-19 * the whole document *;
 [X]US2002013263  (HSIA JEN-CHANG [US]) [X] 1-9,11,13,14,17,18 * paragraphs [0002] , [0 39] * * examples 1-16 *;
 [XI]US2015094267  (VANDEGRIFF KIM D [US], et al) [X] 1-9,11,13,14,17,18 * paragraph [0208] * * examples 1-9 * [I] 10,12,15,16,19;
 [T]  - SHANTA M. MESSERLI ET AL, "Use of Antimetastatic SOD3-Mimetic Albumin as a Primer in Triple Negative Breast Cancer", JOURNAL OF ONCOLOGY, US, (20190228), vol. 2019, doi:10.1155/2019/3253696, ISSN 1687-8450, pages 1 - 11, XP055602488 [T] * the whole document *

DOI:   http://dx.doi.org/10.1155/2019/3253696
International search[Y]US2002013263  (HSIA JEN-CHANG [US]) [Y] 1-4, 6-16 * ; para[0039] para[0045] para[0054] para[0122] para[0234] para[0262] para[0275] *;
 [A]US2004024025  (KASID USHA [US], et al) [A] 1-16* ; entrire document *;
 [XY]  - YU et al., "A pH dependent thermo-sensitive copolymer drug carrier incorporating 4-amino- 2,2,6,6-tetramethylpiperidin-1-oxyl (4-NH2-TEMPO) residues for electron spin resonance (ESR) labeling", Journal of Colloid and Interface Science, (20110707), vol. 362, pages 584 - 593, XP 028261837 [X] 5 * ;page586,page592,page593 * [Y] 12
 [Y]  - SOULE et al., "Therapeutic and Clinical Applications of Nitroxide Compounds", Antioxidant & Redox Signaling, (20071110), vol. 9, no. 10, pages 1731 - 1743, XP 055390502 [Y] 1-4, 6-16 * ; page1738 *
 [Y]  - SIROVICH et al., "Activity of Ruboxyl, a Nitroxyl Derivative of Daunorubicin, on Experimental Models of Colorectal Cancer Metastases", Tumor Biology, (19990723), vol. 20, no. 5, doi:http://www.karger.com/doi/10.1159/000030074, pages 270 - 276, XP 009510786 [Y] 6 * ; Abstract *
 [Y]  - DU et al., "Regulation of Pancreatic Cancer Growth by Superoxide", Molecular Carcinogenesis, (20120305), vol. 52, pages 555 - 567, XP 055390615 [Y] 10 * ; page555, page566 *
 [Y]  - Keith Block, "Immune Surveillance: Mounting the immune barricades", Keith Block, Keith Block, Life Over Cancer: The Block Center Program for Integrative Cancer Treatment, (20090421), pages 346 - 367, ISBN 9780553801149, XP009511222 [Y] 9, 11, 14, 16 * ; page349 *
 [Y]  - YAMATO et al., "Tempol intake improves inflammatory status in aged mice", Journal of Clinical Biochemistry and Nutrition, (20140524), vol. 55, pages 11 - 14, XP 003032460 [Y] 9, 11, 14, 16 * ; Abstract *
 [Y]  - NORRELL et al., "Leukoencephalopathy following the administration of methotrexate into the cerebrospinal fluid in the treatment of primary brain tumors", Cancer, (19740400), vol. 33, pages 923 - 932, XP 055390705 [Y] 15 * ; Title *
 [Y]  - GARIBOLDIA et al., "Study of in vitro and in vivo effects of the piperidine nitroxide Tempol-a potential new therapeutic agent for gliomas", European Journal of Cancer, (20030123), vol. 39, pages 829 - 837, XP 004414315 [Y] 15 * ; Abstract *
 [A]  - HASHIDA et al., "Characterization of a Lipophilic Prodrug of 5-Fluorouracil with a Cholesterol Promoiety and lts Application to Liposomes", Chemical and Pharmaceutical Bulletin, (20080331), vol. 36, pages 3186 - 3189, XP 002063290 [A] 12 * ; Title *
by applicantUS5840701
 US2002013263
 US2015094267
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.